Skip to content

Available Limited Access Datasets From NIMH Clinical Trials

Procedures for Requesting Limited Access Datasets

Investigators wishing to request any of the datasets below must obtain and submit a Data Use Certificate (DUC) in order for NIMH to release the dataset. Please note that the DUC requires the institution's Federal Wide Assurance (FWA) number and the signature of the institution's official.

To request a DUC, send an email to: Be sure to specify the dataset that you are requesting.

*NOTE: Trials marked with an asterisk (*) also collected genetics-related biomaterials from willing participants. The biomaterial, genetics data, and companion clinical data for those participants are available from the NIMH Center for Collaborative Genetic Studies  and may be requested under the Center’s Distribution Agreement . These genetics data and companion clinical data are not available from the NIMH Clinical Trials Limited Access Datasets office.

For study descriptions, see the Identifier (NCT Number):

Attention Deficit Hyperactivity Disorder

  • Multimodal Treatment Study of Children with Attention Deficit and Hyperactivity Disorder (MTA) (NCT00000388) 

Alzheimer's Disease

  • Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): in Patients with Alzheimer’s Disease (NCT00015548) 

Anxiety Disorders

  • Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes* (NCT00347269) 
  • Child and Adolescent Anxiety Disorders (CAMS) (NCT00052078) 
  • Research Units in Pediatric Psychopharmacology (RUPP) Studies: Treatment For Anxiety in Children (NCT00000389) 

Autism Spectrum Disorder

  • Research Units in Pediatric Psychopharmacology (RUPP) Studies: Treatment of Autism in Children and Adolescents (NCT00005014) 

Bipolar Disorder

  • Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder (LiTMUS)* (NCT00667745) 
  • Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)* (NCT00012558) 
  • Treatment of Early Age Mania (TEAM) (NCT00057681) 


  • Combining Medications to Enhance Depression Outcomes (CO-MED)* (NCT00590863) 
  • Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP) (NCT00057551) 
  • Sequenced Treatment Alternatives to Relieve Depression (STAR*D)* (NCT00021528) 
  • Study of Pharmacotherapy of Psychotic Depression (STOP-PD) (NCT00056472) 
  • Treatment for Adolescents with Depression Study (TADS)/Substance Use and Other Outcomes Following Treatment for Adolescent Depression (SOFTAD)* (NCT00006286) 
  • Treatment of Major Depression with St. John's Wort (Hypericum) (NCT00005013) 
  • Treatment of SSRI-Resistant Depression In Adolescents (TORDIA) (NCT00018902) 

Pervasive Developmental Disorder

  • Research Units in Pediatric Psychopharmacology (RUPP) Studies: Methylphenidate in Children and Adolescents With Pervasive Development Disorders (NCT00025779) 
  • Research Units in Pediatric Psychopharmacology (RUPP) Studies: Risperidone and Behavior Therapy in Children with Pervasive Developmental Disorders (NCT00080145 )


  • A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS)* (NCT01136772) 
  • Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder (CAMP) (NCT00423878) 
  • Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Schizophrenia* (NCT00014001) 
  • Metformin in the Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia (METS) (NCT00816907) 
  • Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE) (NCT00330863) 
  • Recovery After Initial Episode of Psychosis - Connection Program (Impact Evaluation Study) (RAISE-IES) (NCT01216891) 
  • Treatment of Early Onset Schizophrenia Spectrum Disorders Study (TEOSS) (NCT00053703)